Comparison of Two Liraglutide Formulations in Healthy Subjects

NCT01515579 · Completed

Last updated 2026-05-28

This clinical trial compares two different versions of the diabetes medication liraglutide in healthy adults to see how their bodies absorb and process the drug.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 22 people

Who can join Ages 18–50 · all sexes

Timeline Started 2006-04 · est. completion 2006-06

Where 1 site · Sweden

What this study is testing ClinicalTrials.gov NCT01515579 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of the phase 3a formulation of liraglutide at pH 8.15 (formulation 4) and liraglutide at pH 7.7 (formulation 3).

Treatments tested

liraglutide Drug

One single dose of 6.25 mg/mL administered subcutaneously
liraglutide Drug

One single dose of 6.0 mg/mL administered subcutaneously

Main thing measured	Area under the curve (0-t)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01515579 ↗